One of the newest biocompatibility evaluations tools is extractable and leachable (E&L) testing. A correctly run E&L study, with an accompanying toxicological evaluation, can be used to replace traditional tests like systemic toxicity, genotoxicity, reproductive toxicity, and carcinogenicity. The data gained from these studies can help understand the total risk of your device to an intended population of users; but unlike the traditional animal tests, it comes with separate risks. These tests are not your typical “stamped” tests, where every lab gives a similar quality of results. Because of this, FDA has refined a strict, detailed, list of parameters that should be included in every test. This list is very dynamic and is changing rapidly; the best way to make sure you are performing the correct version of the test is to learn from the most recent FDA feedback on studies.
TAKEAWAY ITEMS: • Understand recent FDA feedback and dissect what FDA is asking/looking for
• Learn how to address these concerns and develop a protocol to make sure you don’t receive similar questions
• Recognize how FDA is using the new ISO 10993-18 and where they deviate from that standard
ABOUT NELSON LABS:
Nelson Labs, a Sotera Health company, is the industry-leading global provider of lab testing and expert consulting services. We perform microbiological and analytical laboratory tests across the medical device, pharmaceutical, and tissue industries. The company is regarded as a best-in-class partner with a strong track record of collaborating with customers to solve complex issues.
With the addition of Nelson Labs Europe, we are the leading global extractables and leachables lab testing platform. We have over 700 scientists, technicians, and service specialists who diligently performing more than 700 rigorous tests in 13 global laboratory locations. With decades of expertise, we stand behind the quality of our results and the strength of our customer partnerships.